Warts - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Warts - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Warts - Pipeline Review, H1 2015', provides an overview of the Warts's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Warts
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Warts
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Warts Overview 8
Therapeutics Development 9
Pipeline Products for Warts - Overview 9
Pipeline Products for Warts - Comparative Analysis 10
Warts - Therapeutics under Development by Companies 11
Warts - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Warts - Products under Development by Companies 15
Warts - Companies Involved in Therapeutics Development 16
3M Drug Delivery Systems 16
Agilvax, Inc. 17
Anaconda Pharma 18
BioMAS Ltd. 19
Burke Pharmaceuticals, LLC 20
Cutanea Life Sciences 21
Foamix Pharmaceuticals Ltd. 22
G&E Herbal Biotechnology Co., Ltd. 23
Helix BioPharma Corp. 24
NanoViricides, Inc. 25
Nielsen Biosciences, Inc. 26
ViroStatics, srl 27
Warts - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(digoxin + furosemide) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
854-A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
A-101 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
AP-611074 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AS-101 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AX-03 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BURKE-201 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Candida Albicans Antigen - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HerpeCide-I - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
imiquimod - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
interferon alpha-2b (recombinant) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PP-210 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SRT-100 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Warts - Recent Pipeline Updates 54
Warts - Dormant Projects 57
Warts - Discontinued Products 58
Warts - Product Development Milestones 59
Featured News & Press Releases 59
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 59
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 59
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 60
Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 61
Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Warts, H1 2015 9
Number of Products under Development for Warts - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Warts - Pipeline by 3M Drug Delivery Systems, H1 2015 16
Warts - Pipeline by Agilvax, Inc., H1 2015 17
Warts - Pipeline by Anaconda Pharma, H1 2015 18
Warts - Pipeline by BioMAS Ltd., H1 2015 19
Warts - Pipeline by Burke Pharmaceuticals, LLC, H1 2015 20
Warts - Pipeline by Cutanea Life Sciences, H1 2015 21
Warts - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 22
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 23
Warts - Pipeline by Helix BioPharma Corp., H1 2015 24
Warts - Pipeline by NanoViricides, Inc., H1 2015 25
Warts - Pipeline by Nielsen Biosciences, Inc., H1 2015 26
Warts - Pipeline by ViroStatics, srl, H1 2015 27
Assessment by Monotherapy Products, H1 2015 28
Assessment by Combination Products, H1 2015 29
Number of Products by Stage and Target, H1 2015 31
Number of Products by Stage and Mechanism of Action, H1 2015 33
Number of Products by Stage and Route of Administration, H1 2015 35
Number of Products by Stage and Molecule Type, H1 2015 37
Warts Therapeutics - Recent Pipeline Updates, H1 2015 54
Warts - Dormant Projects, H1 2015 57
Warts - Discontinued Products, H1 2015 58